Pro-Dex, Inc. Announces Fiscal Second Quarter And Six-Month Results PR Newswire IRVINE, Calif., Jan. 10, 2013 IRVINE, Calif., Jan. 10, 2013 /PRNewswire/ --PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its fiscal second quarter and six months ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20111025/LA93174LOGO-c) Quarter Ended December 31, 2012 Sales for the quarter ended December 31, 2012 decreased 25% to $3.0 million from $4.0 million for the corresponding quarter in 2011. As the Company has previously discussed, this decrease was primarily the result of reductions in purchases of the Company's powered surgical instrument products by its former largest customer, partially offset by increases in such surgical instrument sales to other customers. Excluding sales to the Company's former largest customer, which represented a reduction of $1.5 million in the quarter ended December 31, 2012 from the corresponding quarter in 2011, sales increased $524,000, or 25%, in the quarter ended December 31, 2012. Gross profit for the quarter ended December 31, 2012 was $1.0 million, or 34%, compared to gross profit of $1.2 million, or 31%, for the year-ago period. The increase in gross profit as a percentage of sales from 2011 to 2012 was due primarily to a reduction in warranty costs and improvements in manufacturing efficiencies, partially offset by unfavorable changes in product mix. Operating expenses, which include selling, general and administrative, and research and development expenses, for the quarter ended December 31, 2012 decreased 10% to $1.4 million from $1.6 million in the prior year's corresponding quarter. This decrease was attributable to the effects of reduced employee compensation, other operating expense cuts, and the utilization of engineering resources in contractual revenue-producing activities. Included in operating expenses for the quarter ended December 31, 2012 was $42,000 of legal and other costs associated with the contested election of directors, without which such costs the reduction in operating expenses would have been 12%. Loss from continuing operations for the quarter ended December 31, 2012 was $364,000, compared to a loss from continuing operations of $329,000 in the corresponding quarter in 2011. Net loss for the quarter ended December 31, 2012 was $348,000, or $0.11 per diluted share, compared to a net loss of $292,000, or $0.09 per diluted share, for the corresponding quarter in 2011. Earnings before interest, income taxes and depreciation ("EBITDA") for the quarter ended December 31, 2012 was a loss of $196,000, compared to a loss of $130,000 in the corresponding quarter in 2011. During the quarter ended December 31, 2012, the Company used $619,000 of cash in operating activities. This use of cash reflects primarily payments made in the second fiscal quarter for the build-up of inventory in first fiscal quarter in anticipation of customer orders and pursuant to the Company's operating plan, one of the foundational objectives of which is to reduce production lead times. Six Months Ended December 31, 2012 Sales for the six months ended December 31, 2012 decreased 29% to $6.5 million from $9.1 million in the corresponding six-month period in 2011. Excluding sales to the Company's former largest customer, which represented a reduction of $3.8 million in the six months ended December 31, 2012 from the corresponding period in 2011, sales for the six months ended December 31, 2012 increased $1.2 million, or 25%, in the six months ended December 31, 2012. During the six months ended December 31, 2012, the Company received new orders of $9.4 million, compared to $2.8 million in the corresponding period in 2011, excluding orders received from the former largest customer. The book to bill ratio for the six months ended December 31, 2012 was 1.5. For the six months ended December 31, 2012, gross profit was $2.3 million, or 35%, compared to $3.4 million and 37%, respectively, for the corresponding period in 2011. The decrease in gross profit as a percentage of sales from 2011 to 2012 resulted primarily from reduced manufacturing efficiencies and unfavorable changes in product mix, partially offset by a reduction in warranty costs. Operating expenses for the six months ended December 31, 2012 decreased 19% to $2.7 million, from $3.3 million in the corresponding six-month period of 2011. This decrease was attributable to the effects of reduced employee compensation, other operating expense cuts, and the utilization of engineering resources in contractual revenue-producing activities. For the six months ended December 31, 2012, loss from continuing operations was $418,000, compared to income from continuing operations of $17,000 for the corresponding period in 2011. Net loss for the 2012 six-month period was $365,000, or $0.11 per diluted share, as compared to net income of $154,000, or $0.05 per diluted share, for the corresponding period in 2011. EBITDA for the six months ended December 31, 2012 was a loss of $55,000, compared to income of $473,000 in the corresponding period one year ago. During the six months ended December 31, 2012, the Company used $791,000 of cash in operating activities. This use of cash reflects primarily the previously mentioned build-up of inventory in first fiscal quarter. In addition, as announced previously, in September 2012 the Company repaid the entire outstanding balance on the term loan from Union Bank amounting to $685,000. As a result of the foregoing, cash on hand at December 31, 2012 was $2.5 million, compared to $4.1 million at June 30, 2012. Michael J. Berthelot, the Company's President and Chief Executive Officer, commented, "We believe that the results of the quarter and six months ended December 31, 2012 reflect continued progress on our strategy to move our company forward. We believe that our continuing efforts to attract, quote on and win new business are showing results. In the six months ended December 31, 2011, the first half of fiscal year 2012, we submitted five proposals to potential customers, and submitted eight proposals for the entire fiscal year. So far in this current fiscal year we have already submitted eight proposals in the six months ended December 31, 2012 and have won one of them. As important, the value of the current year proposals in both non-recurring engineering and production value materially exceed those from last year. While we can offer no assurances that we will win any of the business upon which we have quoted, we know that we cannot win any business on which we do not quote. We continue to win business from new customers as well as current customers, as shown in a 25% increase in sales of powered surgical instruments to customers other than our former largest customer compared to last year's corresponding quarter and six-months, and continue to build our backlog with a book to bill ratio of 1.5 for both the quarter and the six months ended December 31, 2012." "Our continuing efforts at cost reduction and improved manufacturing efficiencies led to our gross margin for the quarter ended December 31, 2012 increasing to 34% from 31% in last year's corresponding quarter in spite of a 25% reduction in sales volume and an unfavorable shift in product mix," said Mr. Berthelot. "Our programs to reduce cost in every non-manufacturing department continue to bear fruit, as evidenced by the 10% reduction in operating costs for the quarter from last year. It is important to point out that $42,000 of the general and administrative costs for the quarter are associated with the contested election of directors that we would not normally incur." Mr. Berthelot said, "With respect to product innovation and quality improvement, much of the new proposals discussed above revolve around our Pro-Driver platform and involve various derivatives and modifications to our basic product. While the time-consuming process from initial meeting to proposal, development, testing, acceptance and production may run from twelve to eighteen months and involve resources from sales and marketing, engineering, quality assurance, operations and finance, we have achieved success in winning customer acceptance of our development process and we hope that success will continue on if and when the product is released to production. We have been working on an expansion of our dental product line for several months. With a resurgent marketing effort, we hope to launch a new product that will fill out our dental product line during the next six months. As we push forward our product innovation and development efforts and move to protect our intellectual property, we are seeing greater spending on legal fees associated with patent and trademark filings, which aggregated $22,000 and $47,000 during the quarter and six months ended December 31, 2012, respectively." Mr. Berthelot continued, "Lead times for our most significant products continue to improve. As a result of a change in our production and planning processes, we are now able to ship our standard Pro-Drivers, the product which is currently attracting the most interest from potential customers, within two days of order for small volumes and two weeks for larger volumes, compared to quoted lead times of sixteen weeks in last fiscal year's fourth quarter. We believe that an improved responsiveness to customer requests for samples and small volume test and evaluation lots will help us in our efforts to participate from the early phases of new customer programs." "While we are making progress, we still have much to do. The second quarter was, we believe, the toughest of the fiscal year, partly due to our shutdown of operations for two weeks during the quarter for the Thanksgiving, Christmas and New Year holidays as part of our cost reduction program. Our backlog is strong for the second half of fiscal 2013. We expect to continue to press down on our cost structure while increasing engineering resources. We expect the programs and projects that we have begun to move our company forward and to build value for every shareholder." "Of course," Mr. Berthelot noted, "we appreciate the support of each and every shareholder as we pursue our strategy amidst the distraction and diversion of resources due to the contested election of directors. We understand that there have been some logistical problems in our proxy materials arriving to our shareholders on the West Coast. If you have not yet received the Company's proxy materials which include the BLUE proxy card, we encourage you to contact our proxy solicitor, AST Phoenix Advisers, at 1-866-721-1318 and ask for the materials to be sent to you. We ask that all of our shareholders vote for the Pro-Dex director nominees using the BLUE proxy card as quickly as possible, and we thank you for your support." Teleconference Information: Investors and analysts are invited to listen to a broadcast review of the Company's fiscal 2013 second quarter and six-month financial results today at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) that may be accessed by visiting the Company's website at www.pro-dex.com. The conference call may also be accessed at www.InvestorCalendar.com. Investors and analysts who would like to participate in the conference call may do so via telephone at (877) 407-8033, or at (201) 689-8033 if calling from outside the U.S. or Canada. For those who cannot access the live broadcast, a replay will be available approximately two hours after the completion of the call until midnight (Eastern Time) on January 24, 2013 by calling (877) 660-6853, or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 407053. An online archive of the broadcast will be available on the Company's website www.pro-dex.com for a period of 365 days. About Pro-Dex, Inc.: Pro-Dex, Inc., with operations in California and Oregon, specializes in the design, development and manufacture of powered rotary drive surgical and dental instruments used primarily in the orthopedic, spine, maxocranial facial and dental markets. Its OMS division designs and manufactures embedded motion control systems serving the medical, dental, semi-conductor and scientific research markets. Pro-Dex's products are found in hospitals, dental offices, medical engineering labs, scientific research facilities and high tech manufacturing operations around the world. For more information, visit the Company's website at www.pro-dex.com. Statements herein concerning the Company's plans, growth and strategies may include 'forward-looking statements' within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business concerns of the Company set forth in the Company's filings with the Securities and Exchange Commission. (tables follow) PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED BALANCE SHEETS December31,2012 June30,2012 ASSETS Current assets: Cash $ 2,549,000 $ 4,112,000 Accounts receivable, net of allowance for doubtful accounts of $13,000 at December31, 1,175,000 1,581,000 2012 and $16,000 at June30, 2012 Other current receivables 90,000 123,000 Inventories 3,515,000 2,791,000 Prepaid expenses 237,000 172,000 Income taxes receivable 570,000 609,000 Deferred income taxes 109,000 109,000 Total current assets 8,245,000 9,497,000 Property, plant, equipment and leasehold 2,290,000 2,539,000 improvements, net Real estate held for sale 733,000 733,000 Other assets 53,000 53,000 Total assets $ 11,321,000 $ 12,822,000 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 576,000 $ 633,000 Accrued expenses 1,008,000 1,425,000 Income taxes payable 47,000 47,000 Bank term loan -- 774,000 Total current liabilities 1,631,000 2,879,000 Non-current liabilities: Deferred income taxes 109,000 109,000 Deferred rent 280,000 284,000 Total non-current liabilities 389,000 393,000 Total liabilities 2,020,000 3,272,000 Commitments and contingencies Shareholders' equity: Common shares; no par value; 50,000,000 shares authorized; 3,340,684 and 3,272,350 shares issued and outstanding at 16,962,000 16,846,000 December31, 2012 and June30, 2012, respectively Accumulated deficit (7,661,000) (7,296,000) Total shareholders' equity 9,301,000 9,550,000 Total liabilities and shareholders' equity $ 11,321,000 $ 12,822,000 PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS ForTheThreeMonthsEndedDecember31, 2012 2011 Net sales $ 3,007,000 $ 4,017,000 Cost of sales 1,974,000 2,770,000 Gross profit 1,033,000 1,247,000 Operating expenses: Selling expenses 322,000 369,000 General and administrative expenses 627,000 688,000 Research and development costs 464,000 508,000 Total operating expenses 1,413,000 1,565,000 Loss from continuing operations before (380,000) (318,000) items below Other expense: Interest expense -- (10,000) Total other expense -- (10,000) Loss from continuing operations before provision for (benefit from) income (380,000) (328,000) taxes Provision for (benefit from) income (16,000) 1,000 taxes Loss from continuing operations (364,000) (329,000) Income from discontinued operations, net of provision for income taxes of 16,000 37,000 $21,000 in 2012 and $0 in 2011 Net loss $ (348,000) $ (292,000) Per share data: Loss from continuing operations Basic $ (0.11) $ (0.10) Diluted $ (0.11) $ (0.10) Income from discontinued operations Basic $ -- $ 0.01 Diluted $ -- $ 0.01 Net loss Basic $ (0.11) $ (0.09) Diluted $ (0.11) $ (0.09) Weighted average shares outstanding - 3,319,180 3,272,350 basic Weighted average shares outstanding - 3,319,180 3,272,350 diluted PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS ForTheSixMonthsEndedDecember31, 2012 2011 Net sales $ 6,468,000 $ 9,062,000 Cost of sales 4,199,000 5,707,000 Gross profit 2,269,000 3,355,000 Operating expenses: Selling expenses 596,000 743,000 General and administrative expenses 1,234,000 1,504,000 Research and development costs 870,000 1,069,000 Total operating expenses 2,700,000 3,316,000 Income (loss) from continuing operations (431,000) 39,000 before items below Other expense: Interest expense (6,000) (20,000) Total other expense (6,000) (20,000) Income (loss) from continuing operations before provision for (benefit from) (437,000) 19,000 income taxes Provision for (benefit from) income (19,000) 2,000 taxes Income (loss) from continuing operations (418,000) 17,000 Income from discontinued operations, net of provision for income taxes of $25,000 53,000 137,000 in 2012 and $0 in 2011 Net income (loss) $ (365,000) $ 154,000 Per share data: Income (loss) from continuing operations Basic $ (0.13) $ 0.01 Diluted $ (0.13) $ 0.01 Income from discontinued operations Basic $ 0.02 $ 0.04 Diluted $ 0.02 $ 0.04 Net income (loss) Basic $ (0.11) $ 0.05 Diluted $ (0.11) $ 0.05 Weighted average shares outstanding - 3,299,379 3,272,350 basic Weighted average shares outstanding - 3,299,379 3,292,508 diluted PRO-DEX, INC. and SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS ForTheSixMonthsEndedDecember31, 2012 2011 Cash flows from operating activities: Net income (loss) $ (365,000) $ 154,000 Adjustments to reconcile net income (loss) to net cash used in operating activities: Depreciation and amortization 298,000 339,000 Allowance for doubtful accounts (3,000) 6,000 Share-based compensation 65,000 33,000 Changes in: Accounts receivable and other 440,000 834,000 current receivables Inventories (724,000) (1,030,000) Prepaid expenses (65,000) (88,000) Other assets -- 8,000 Accounts payable and accrued (476,000) (213,000) expenses Income taxes receivable and payable 39,000 (49,000) Net cash used in operating (791,000) (6,000) activities Cash flows from investing activities: Purchases of equipment (48,000) (237,000) Net cash used in investing (48,000) (237,000) activities Cash flows from financing activities: Proceeds from exercise of stock 50,000 -- options Principal payments on term loan (774,000) (179,000) Net cash used in financing (724,000) (179,000) activities Net decrease in cash (1,563,000) (422,000) Cash, beginning of period 4,112,000 4,689,000 Cash, end of period $ 2,549,000 $ 4,267,000 Supplemental Information Cash payments for interest $ 9,000 $ 10,000 Cash payments for income taxes $ — $ — PRO-DEX, INC. and SUBSIDIARIES RECONCILIATION OF NON-GAAP DATA TO GAAP DATA Loss From Continuing Operations Before Provision For Income Taxes (in thousands) (unaudited) For The Three Months Ended For The Six Months Ended December 31, December 31, 2012 2011 2012 2011 Earnings before interest, taxes, depreciation and $(196,000) $(130,000) $(55,000) $473,000 amortization ("EBITDA") Interest expense -- 10,000 6,000 20,000 Depreciation and 147,000 151,000 298,000 297,000 amortization Income from discontinued operations, before provision for income taxes of $21,000 and $25,000 for the three and six months 37,000 37,000 78,000 137,000 ended December 31, 2012, respectively, and $0 for each of the three and six months ended December 31, 2011 Income (loss) from continuing operations $(380,000) $(328,000) $(437,000) $19,000 before provision for income taxes SOURCE Pro-Dex, Inc. Website: http://www.pro-dex.com Contact: Michael J. Berthelot, Chief Executive Officer, +1-949-769-3200
Glaxo to Pay $488.7 Million Fine to End China Corruption Probe
Pro-Dex, Inc. Announces Fiscal Second Quarter And Six-Month Results
Press spacebar to pause and continue. Press esc to stop.